Animal study shows niacin reduces miR-93 levels and enhances liver function — Evidence Review

Researchers have identified a genetic regulator, miR-93, as a key driver of metabolic-associated fatty liver disease (MASLD) and found that niacin (vitamin B3) can target this pathway to improve liver health, according to a new study from UNIST and collaborators. Related studies generally support niacin’s beneficial effects on liver fat and inflammation, while miR-93’s role in liver disease is a newer area of investigation.

• Multiple animal and cell studies have previously shown that niacin reduces hepatic fat accumulation, inflammation, and oxidative stress in models of non-alcoholic fatty liver disease (NAFLD), consistent with this study’s findings that niacin improves liver fat processing via molecular pathways 1 2 5.
• While miR-93 has been connected to cancer progression and cell proliferation in liver cancer models, its direct role in fatty liver disease pathogenesis is less well studied, making this a novel contribution that both expands and refines current knowledge 6 7 8 10.
• The translational relevance is strengthened by earlier research showing that niacin can lower liver fat content in both animals and humans, and by the identification of specific genetic and enzymatic targets (such as DGAT2 and SIRT1) involved in these effects 2 3 5.

Study Overview and Key Findings

Metabolic-associated fatty liver disease (MASLD) affects nearly one-third of people worldwide but has lacked targeted treatments. This study is significant because it uncovers a previously underappreciated molecular pathway—miR-93 regulation—that drives fat accumulation and inflammation in the liver. Importantly, it demonstrates that an existing, widely available therapy, niacin (vitamin B3), can reverse these harmful effects by modulating miR-93 and its downstream targets. By connecting a well-known drug to a new molecular mechanism, the research highlights a potentially rapid path to clinical application for a condition with limited therapeutic options.

Property	Value
Organization	UNIST, Pusan National University, Ulsan University Hospital
Journal Name	Metabolism: Clinical and Experimental
Authors	Jang Hyun Choi, Hwayoung Yun, Neung Hwa Park, Yo Han Lee, Kieun Park, Joonho Jeong, Jinyoung Lee
Population	Mice with fatty liver disease
Methods	Animal Study
Outcome	miR-93 levels, SIRT1 activity, liver fat processing
Results	Niacin reduced miR-93 levels and improved liver function in mice.

Literature Review: Related Studies

To evaluate how these findings fit within the broader scientific landscape, we searched the Consensus database of over 200 million research papers. The following search queries were used to identify relevant studies:

1. niacin fatty liver function improvement
2. miR-93 levels liver disease treatment
3. vitamin effects on liver health

Below is a summary of key topics and findings from related research:

Topic	Key Findings
How does niacin (vitamin B3) affect liver fat and inflammation in fatty liver disease?	- Niacin reduces hepatic fat accumulation, oxidative stress, and inflammatory cytokines in both animal and cell models 1 2 5. - Niacin’s effects may be mediated by inhibition of triglyceride synthesis enzymes and activation of signaling pathways that reduce lipogenesis 2 5.
What is the role of miR-93 in liver disease and metabolic regulation?	- miR-93 is upregulated in liver cancer and linked to increased cell proliferation, migration, and invasion, but its direct involvement in fatty liver disease pathogenesis is newly reported 6 7 8 10. - Some evidence suggests miR-93 modulates inflammation and injury responses in the liver 9.
How do other vitamins (E, D) compare in terms of fatty liver disease treatment efficacy?	- Vitamin E improves liver function and histological features in NAFLD and NASH patients, as supported by multiple meta-analyses and observational studies 11 12 15. - Vitamin D’s benefit in chronic liver disease is less clear, with mixed or inconclusive findings in meta-analyses 13 14.
Can genetic or molecular factors influence individual responses to vitamin therapy in fatty liver?	- Variants in genes such as DGAT2 may alter the degree of liver fat reduction in response to niacin therapy 3. - Changes in molecular pathways (e.g., SIRT1, GPR109A) are associated with the beneficial effects of vitamins on liver metabolism 5.

How does niacin (vitamin B3) affect liver fat and inflammation in fatty liver disease?

A consistent body of research demonstrates that niacin reduces liver fat accumulation and inflammation in both animal and cell models of fatty liver disease. The new study aligns with these findings by showing that niacin lowers miR-93 levels and restores fat metabolism via SIRT1, providing a new molecular mechanism for these beneficial effects.

• Niacin supplementation in rodent models of fatty liver disease leads to lower hepatic triglycerides, reduced oxidative stress, and decreased inflammatory markers such as IL-8 1 2 5.
• The mechanism of action involves inhibition of diacylglycerol acyltransferase 2 (DGAT2) and modulation of signaling pathways that govern lipid synthesis, such as GPR109A-mediated AMPK activation 2 5.
• Human studies also suggest that niacin can reduce liver fat content, although genetic factors may influence the extent of benefit 3.
• The new study builds upon these mechanistic insights by linking niacin’s effects to the suppression of miR-93 and activation of SIRT1, a regulator of hepatic fat metabolism 1 2 5.

What is the role of miR-93 in liver disease and metabolic regulation?

Previous research has primarily focused on miR-93’s role in liver cancer, where it promotes cell proliferation and invasion. Its direct involvement in fatty liver disease is a novel finding, as most earlier studies linked miR-93 to tumorigenesis rather than metabolic dysfunction.

• miR-93 is overexpressed in hepatocellular carcinoma (HCC) and is associated with poor prognosis and aggressive tumor characteristics 6 7 8 10.
• In HCC, miR-93 targets tumor suppressor genes (e.g., PTEN, PDCD4, TIMP2) and activates oncogenic pathways such as c-Met/PI3K/Akt 6 7 8 10.
• Limited evidence suggests that miR-93 can modulate inflammation and injury in the liver, but its impact on fatty liver disease progression was not previously established 9.
• The new study extends miR-93’s relevance from cancer biology to metabolic liver disease, uncovering its role in fat accumulation and insulin sensitivity 6 7 8 10.

How do other vitamins (E, D) compare in terms of fatty liver disease treatment efficacy?

Vitamin E has shown consistent benefits in improving liver function and histological parameters in NAFLD and NASH, while evidence for vitamin D is less robust. The new study’s focus on niacin adds another vitamin-based approach to the field, with a distinct molecular target.

• Meta-analyses and observational studies report that vitamin E supplementation leads to significant improvements in liver enzymes, steatosis, inflammation, and even transplant-free survival in NAFLD and NASH patients 11 12 15.
• Vitamin D supplementation’s impact on liver outcomes remains unclear, with systematic reviews noting insufficient evidence for meaningful effects on mortality or liver-related morbidity 13 14.
• Both vitamin E and niacin appear to have favorable safety profiles when used appropriately, supporting their roles as adjuncts or alternatives in managing fatty liver disease 11 12 15.
• The new study provides mechanistic depth by highlighting niacin’s action on miR-93/SIRT1, whereas most vitamin E and D studies focus on antioxidant or immunomodulatory effects 11 12 13 14 15.

Can genetic or molecular factors influence individual responses to vitamin therapy in fatty liver?

There is evidence that individual genetic variants and molecular pathway differences can affect the efficacy of vitamin interventions, particularly for niacin. The new study’s identification of the miR-93/SIRT1 axis adds to this personalized medicine perspective.

• Hepatic fat reduction with niacin may be less pronounced in individuals with certain DGAT2 gene polymorphisms, suggesting a genetic influence on treatment response 3.
• Niacin’s efficacy is also linked to its ability to activate specific molecular pathways, such as GPR109A-mediated inhibition of lipogenesis 5.
• The new research introduces miR-93 expression levels as another potential biomarker or therapeutic target for stratifying patients and predicting treatment outcomes 1 2 3 5.
• These insights underscore the need for personalized approaches in fatty liver disease management, considering both genetic and molecular factors 3 5.

Future Research Questions

While the new findings offer promising insights and potential therapeutic avenues, further research is needed to address several gaps. Questions remain about the translation of animal results to humans, the long-term safety and efficacy of niacin in MASLD, and the broader role of miR-93 in liver and metabolic health.

Research Question	Relevance
Does niacin reduce liver fat and improve liver function in humans with MASLD?	Human trials are needed to confirm whether the benefits seen in mice translate to clinical improvements in people with MASLD 3.
What are the long-term safety and efficacy profiles of niacin treatment for fatty liver disease?	While niacin has a favorable safety record for hyperlipidemia, its safety and sustained efficacy in fatty liver disease populations require further evaluation 3 5.
How does miR-93 expression vary in different types and stages of liver disease?	Understanding miR-93’s role across the spectrum of liver diseases (from NAFLD to NASH to HCC) may reveal whether it is a general driver or specific to certain disease stages 6 7 8 10.
Are there predictive biomarkers (for example, DGAT2 or miR-93) that can identify patients most likely to benefit from niacin?	Individual genetic and molecular factors may modify response to niacin, and identifying such biomarkers would enable personalized therapy 3 5.
How does combination therapy with niacin and other vitamins (E, D) affect liver outcomes in MASLD?	Exploring additive or synergistic effects of vitamin combinations could improve treatment efficacy, given the supportive evidence for vitamin E and possible benefit of vitamin D 11 12 15.

---

This article provides a concise synthesis of the latest findings and contextualizes them within the broader scientific literature, highlighting areas of consensus and ongoing uncertainty in the field of fatty liver disease research.